Voriconazole (Synonyms: DRG 0301, UK 109496, VRC) |
| رقم الكتالوجGC13079 |
A triazole antifungal agent
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 137234-62-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Voriconazole is an inhibitor of 14α-lanosterol demethylase with IC50 value of 53nM [1].
Voriconazole is a triazole antifungal and a second-generation synthetic derivative of fluconazole. It plays its antifungal role through inhibiting cytochrome P450 (CYP 450)–dependent 14α-lanosterol demethylation, which is a vital step in the membrane ergosterol synthesis of fungi. Voriconazole has a broad antifungal spectrum. It is active against all Candida species, many Aspergillus species and other yeasts, including Cryptococcus neoformans, Trichosporon beigelii, and Saccharomyces cerevisia. Voriconazole is available in both intravenous and oral formulations. Voriconazole undergoes extensive hepatic metabolism via the cytochrome P450 enzymes, primarily CYP2C9 and CYP3A4. In addition, voriconazole also causes some side effects, such as visual disturbances, skin rashes and elevations in hepatic enzyme levels [1, 2].
References:
[1] Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann Pharmacother. 2000 Sep;34(9):1032-43.
[2] Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003 Mar 1;36(5):630-7.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *